These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 22297136)

  • 1. Cross-reactive antibody to swine influenza A(H3N2) subtype virus in children and adults before and after immunisation with 2010/11 trivalent inactivated influenza vaccine in Canada, August to November 2010.
    Skowronski DM; De Serres G; Janjua NZ; Gardy JL; Gilca V; Dionne M; Hamelin ME; Rhéaume C; Boivin G
    Euro Surveill; 2012 Jan; 17(4):. PubMed ID: 22297136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v).
    Skowronski DM; Janjua NZ; De Serres G; Purych D; Gilca V; Scheifele DW; Dionne M; Sabaiduc S; Gardy JL; Li G; Bastien N; Petric M; Boivin G; Li Y
    J Infect Dis; 2012 Dec; 206(12):1852-61. PubMed ID: 22872731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents.
    Munoz FM; Anderson EJ; Bernstein DI; Harrison CJ; Pahud B; Anderson E; Creech CB; Berry AA; Kotloff KL; Walter EB; Atmar RL; Bellamy AR; Chang S; Keitel WA
    Vaccine; 2019 Aug; 37(36):5161-5170. PubMed ID: 31375440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies cross-reactive to influenza A (H3N2) variant virus and impact of 2010-11 seasonal influenza vaccine on cross-reactive antibodies - United States.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Apr; 61(14):237-41. PubMed ID: 22495226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses.
    Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B
    Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-related prevalence of cross-reactive antibodies against influenza A(H3N2) variant virus, Germany, 2003 to 2010.
    Blümel B; Schweiger B; Dehnert M; Buda S; Reuss A; Czogiel I; Kamtsiuris P; Schlaud M; Poethko-Müller C; Thamm M; Haas W
    Euro Surveill; 2015 Aug; 20(32):16-24. PubMed ID: 26290488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lower seroreactivity to European than to North American H3N2 swine influenza viruses in humans, Luxembourg, 2010.
    Qiu Y; Muller CP; Van Reeth K
    Euro Surveill; 2015 Apr; 20(13):25-33. PubMed ID: 25860393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population susceptibility to North American and Eurasian swine influenza viruses in England, at three time points between 2004 and 2011.
    Hoschler K; Thompson C; Casas I; Ellis J; Galiano M; Andrews N; Zambon M
    Euro Surveill; 2013 Sep; 18(36):pii=20578. PubMed ID: 24079379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007.
    Skowronski DM; De Serres G; Dickinson J; Petric M; Mak A; Fonseca K; Kwindt TL; Chan T; Bastien N; Charest H; Li Y
    J Infect Dis; 2009 Jan; 199(2):168-79. PubMed ID: 19086914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trivalent inactivated influenza vaccine effective against influenza A(H3N2) variant viruses in children during the 2014/15 season, Japan.
    Sugaya N; Shinjoh M; Kawakami C; Yamaguchi Y; Yoshida M; Baba H; Ishikawa M; Kono M; Sekiguchi S; Kimiya T; Mitamura K; Fujino M; Komiyama O; Yoshida N; Tsunematsu K; Narabayashi A; Nakata Y; Sato A; Taguchi N; Fujita H; Toki M; Myokai M; Ookawara I; Takahashi T
    Euro Surveill; 2016 Oct; 21(42):. PubMed ID: 27784529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Swine influenza virus and the recycling of influenza-A viruses in man.
    Masurel N
    Lancet; 1976 Jul; 2(7979):244-7. PubMed ID: 59252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination-challenge studies with a Port Chalmers/73 (H3N2)-based swine influenza virus vaccine: Reflections on vaccine strain updates and on the vaccine potency test.
    De Vleeschauwer A; Qiu Y; Van Reeth K
    Vaccine; 2015 May; 33(20):2360-6. PubMed ID: 25804707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-dependent prevalence of antibodies cross-reactive to the influenza A(H3N2) variant virus in sera collected in Norway in 2011.
    Waalen K; Kilander A; Dudman SG; Ramos-Ocao R; Hungnes O
    Euro Surveill; 2012 May; 17(19):. PubMed ID: 22607964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with 2014-15 Seasonal Inactivated Influenza Vaccine Elicits Cross-Reactive Anti-HA Antibodies with Strong ADCC Against Antigenically Drifted Circulating H3N2 Virus in Humans.
    Zhong W; Gross FL; Holiday C; Jefferson SN; Bai Y; Liu F; Katz JM; Levine MZ
    Viral Immunol; 2016 May; 29(4):259-62. PubMed ID: 26950058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season.
    Skowronski DM; Janjua NZ; De Serres G; Winter AL; Dickinson JA; Gardy JL; Gubbay J; Fonseca K; Charest H; Crowcroft NS; Fradet MD; Bastien N; Li Y; Krajden M; Sabaiduc S; Petric M
    Clin Infect Dis; 2012 Aug; 55(3):332-42. PubMed ID: 22539661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses.
    Ansaldi F; Canepa P; Ceravolo A; Valle L; de Florentiis D; Oomen R; Vogel FR; Denis M; Samson SI; Icardi G
    Vaccine; 2012 Apr; 30(18):2908-13. PubMed ID: 22342501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
    Tsurudome Y; Kimachi K; Okada Y; Matsuura K; Ooyama Y; Ibaragi K; Kino Y; Ueda K
    Microbiol Immunol; 2015 Oct; 59(10):597-604. PubMed ID: 26272602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partial Protection Induced by 2011-2012 Influenza Vaccine Against Serologically Evidenced A(H3N2) Influenza Virus Infections in Elderly Institutionalized People.
    Camilloni B; Basileo M; Menculini G; Tozzi P; Iorio AM
    Adv Exp Med Biol; 2016; 897():45-53. PubMed ID: 26577530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.